Experimental drug trial seeks to improve treatment for head and neck cancer

November 24, 2017, Cancer Research UK
Experimental drug trial seeks to improve treatment for head and neck cancer
Credit: Cancer Research UK

A trial to test an experimental drug in patients with head and neck cancer launches in the UK today (Friday), through the Combinations Alliance – a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network.

Researchers want to find out whether using Astra Zeneca's AZD1775 experimental compound, in combination with chemotherapy before surgery or with chemotherapy and radiotherapy after surgery, is more effective and reduces the risk of the cancer returning.

They also want to find out if the combination of AZD1775 and chemotherapy before surgery decreases the need for further treatment after surgery.

The phase 1 trial will determine whether it is safe to combine AZD1775 with pre-surgery cisplatin chemotherapy and post-surgery cisplatin chemotherapy and radiotherapy in patients with head and neck cancer, and what dose is best. AZD1775 acts as a potent inhibitor of WEE1, a protein which regulates the cell cycle, and it has been shown to increase the effectiveness of both cisplatin chemotherapy and radiotherapy in pre-clinical studies. It is one of AstraZeneca's portfolio of DNA Damage Response compounds.

There will be two groups of up to 21 patients taking part in the trial co-ordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham. The first group will receive AZD1775 with chemotherapy before surgery and the second will receive AZD1775 in addition to chemotherapy and radiotherapy after surgery.

Standard treatment for high-risk head and neck cancer is surgery followed by cisplatin chemotherapy and radiotherapy. While this treatment is the most effective option for patients, survival is still poor and the treatment often has a significant impact on quality of life for survivors.

Professor Hisham Mehanna, chief investigator of the trial based at the Institute of Cancer and Genomic Studies at the University of Birmingham, said: "Many patients diagnosed with aggressive types of head and neck cancer are at a high risk of relapse after surgery, so we urgently need to find new ways to treat the disease and reduce the risk of it returning.

"We hope that combining this drug with chemotherapy will mean that treatment is more effective helping more people survive, and that those cured will have a better quality of life after treatment."

Anthony Johnson, VP Early Clinical Development, Innovative Medicines and Early Development Biotech Unit at AstraZeneca, said: "We are excited about this new clinical trial evaluating AZD1775 in combination with and radiation in head and neck cancer patients. There is a strong scientific rationale for running this trial and we hope that this will bring clinical benefit to patients."

Researchers on this window-of-opportunity trial are accepting treatment naïve patients between the age of 18 and 70 with of the mouth, throat and voice box and are due to undergo .

Dr Ian Walker, Cancer Research UK's director of clinical research, said: "We're excited to have the opportunity to trial this new drug through our Combinations Alliance initiative. The initiative allows us to bring together combinations of treatments, using drugs that are in development, that wouldn't otherwise be possible. And we look forward to seeing if this drug can improve options for with head and ."

Explore further: Cancer patients diagnosed early are more likely to avoid chemotherapy

Related Stories

Cancer patients diagnosed early are more likely to avoid chemotherapy

October 26, 2017
Cancer patients are around five times more likely to have surgery to remove their tumour, and less likely to have chemotherapy, if they are diagnosed at the earliest stage compared to the latest stage, according to new figures.

Patient profile impacts QOL with radiation Tx in head, neck cancer

August 11, 2017
(HealthDay)—There are patient characteristics and clinical factors independently associated with physical and mental quality of life (QOL) in patients with head and neck cancer undergoing radiotherapy, according to a study ...

Study confirms chemoradiation is best treatment for locally advanced cervical cancer

September 11, 2017
A 14-year randomised trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 ...

Immunotherapy is first to show survival benefit in head and neck cancer

April 19, 2016
The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.

New chemotherapy approach offers breast cancer patients a better quality of life

June 6, 2017
The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin. These are the ...

Pancreatic cancer trial to make tumours more sensitive to treatment

August 30, 2016
Cancer Research UK (CRUK) launches a first-of-its-kind pancreatic cancer clinical trial to make cancer cells more responsive to chemotherapy and radiotherapy, with University of Glasgow researcher Professor Jeff Evans as ...

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.